RT info:eu-repo/semantics/article
T1 Antifungal treatment with echinocandins: a 10-year clinical experience
A1 Poves Álvarez, Rodrigo
A1 Cano Hernández, Beatriz
A1 Balbás Álvarez, Sara
A1 Román García, Patricia
A1 Heredia Rodríguez, María
A1 Gómez Sánchez, Esther
A1 Gómez Pesquera, Estefanía
A1 Lorenzo López, Mario
A1 Martínez Rafael, Beatriz
A1 Muñoz Moreno, María Fe
A1 Eiros Bouza, José María
A1 Tamayo Gómez, Eduardo
K1 Candidemia
K1 Antifungal
K1 Antifúngicos
K1 Echinocandins
K1 Equinocandinas
K1 Mortality
K1 Mortalidad
AB Introduction: The number of studies evaluating the use of echinocandins, whether or not its indication meets international guidelines, in clinical practice is limited. The objective of the present study was to determine the use of echinocandins in a tertiary Spanish hospital in 10 years of clinical practice, and to evaluate its impact on prognosis. Methods: This retrospective study involved adult non-neutropenic ill patients with suspicion of fungal invasion who started treatment with echinocandins between 2006 and 2015. Results: The number of patients treated with echinocandins was 153, and candidemia was detected thereafter in 25.5%.  Factors associated with in-hospital mortality in patients receiving echinocandins were: sex male, septic shock, Charlson comorbidity index, and total stay at the hospital. In-hospital mortality after 7, 30 and 90 days was 13.7%, 24.8%, and 56.8%, respectively. From patients receiving echinocandins, 98 did no show multifocal colonization, 50 had Candida score <2.5, and 49 did not meet Ostrosky-Zeichner prediction rule. A total of 19 patients did not show any of these 3 potential risk factors for candidemia. Conclusions: The use of echinocandins in 10 years of clinical practice in our tertiary hospital has been performed according to international guidelines; however, candidemia was only diagnosed thereafter in only 25.5% of cases. Furthermore, according to our results, the adequate use of echinocandins seems not to be associated with reduced mortality rates. Further studies, involving a large cohort of patients and more hospitals, are required to corroborate these results
PB Sociedad Española de Quimioterapia
SN 0214-3429
YR 2017
FD 2017
LK http://uvadoc.uva.es/handle/10324/45520
UL http://uvadoc.uva.es/handle/10324/45520
LA eng
NO Revista Española de Quimioterapia, 2017, vol. 30, n. 6. p. 413-421
NO Producción Científica
DS UVaDOC
RD 30-abr-2024